A Letter from Omixon CEO, Dr. Peter Meintjes

30/01/2018

Dear Customers and Friends of Omixon, 2017 was one heck of a year – a year filled with growth and change; the year the Orville Omixon took flight to unchartered territories (and beyond?). Back in January 2017 we moved our company offices for the second time in our history,...

Omixon HLA Twin RUO 2.5.0 New Release

29/01/2018

We are excited to announce a release for HLA Twin RUO version 2.5.0. – the world’s most accurate, high throughput HLA genotyping software. Here is the list of new features and improvements: New features and improvements Holotype HLA v2 kit support: Assay version selector allows user to select the...

The Year in Blog Posts – Favourite Announcements from 2017

19/12/2017

As the year ends, we think about all we are grateful for. It has indeed been a pleasure working with you throughout this year and we believe that our amazing sequel will continue. From events to product releases, from new hires to an impressive distributor network we’ve done well! We...

How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

15/12/2017

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017 While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA...

Continued Innovation – Holotype HLA V2.2

30/11/2017

Omixon is delighted to announce the latest evolution of our world-leading HLA Typing product – Holotype HLA V2.1 and V2.2. Both versions deliver improved amplification robustness, increased allele coverage across Class II loci and decreased the library preparation turnaround time to ~4.3h. The major difference between V2.1 and V2.2...